ATE429217T1 - Nateglinid enthaltende hydrophile arzneimittelpräparate - Google Patents

Nateglinid enthaltende hydrophile arzneimittelpräparate

Info

Publication number
ATE429217T1
ATE429217T1 AT01976818T AT01976818T ATE429217T1 AT E429217 T1 ATE429217 T1 AT E429217T1 AT 01976818 T AT01976818 T AT 01976818T AT 01976818 T AT01976818 T AT 01976818T AT E429217 T1 ATE429217 T1 AT E429217T1
Authority
AT
Austria
Prior art keywords
preparation
nateglinide
hydrophilic
preparations containing
medicinal preparations
Prior art date
Application number
AT01976818T
Other languages
English (en)
Inventor
Nobutaka Ninomiya
Chisato Makino
Akira Yabuki
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE429217T1 publication Critical patent/ATE429217T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
AT01976818T 2000-10-24 2001-10-23 Nateglinid enthaltende hydrophile arzneimittelpräparate ATE429217T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324374 2000-10-24
PCT/JP2001/009292 WO2002040010A1 (fr) 2000-10-24 2001-10-23 Preparations de medicament contenant du nateglinide

Publications (1)

Publication Number Publication Date
ATE429217T1 true ATE429217T1 (de) 2009-05-15

Family

ID=18801919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01976818T ATE429217T1 (de) 2000-10-24 2001-10-23 Nateglinid enthaltende hydrophile arzneimittelpräparate

Country Status (19)

Country Link
US (1) US20040029968A1 (de)
EP (1) EP1334721B1 (de)
JP (3) JPWO2002040010A1 (de)
KR (1) KR100829410B1 (de)
CN (1) CN100531730C (de)
AT (1) ATE429217T1 (de)
AU (1) AU2001296000A1 (de)
BR (1) BR0114897A (de)
CA (1) CA2426764C (de)
CY (1) CY1110320T1 (de)
DE (1) DE60138476D1 (de)
DK (1) DK1334721T3 (de)
ES (1) ES2321911T3 (de)
MX (1) MXPA03003686A (de)
PT (1) PT1334721E (de)
RU (1) RU2283104C2 (de)
SI (1) SI1334721T1 (de)
TW (1) TWI289461B (de)
WO (1) WO2002040010A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1437483A (zh) * 1999-12-28 2003-08-20 味之素株式会社 口服给药用糖尿病药物制剂
CN100352432C (zh) * 2000-10-24 2007-12-05 味之素株式会社 含有那格列奈的制剂
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
KR20120064735A (ko) * 2004-04-01 2012-06-19 아지노모토 가부시키가이샤 나테글리니드 함유 제제
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
WO2013066278A1 (en) * 2011-11-03 2013-05-10 Mahmut Bilgic A process for production of pharmaceutical formulations comprising nateglinide
WO2013115740A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Synergisctic combination comprising a meglitinide derivative and lipoic acid
BR112022017578A2 (pt) * 2020-03-27 2022-10-18 Pfizer Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066532B2 (ja) * 1983-09-29 1994-01-26 日産化学工業株式会社 親水性コロイドにより変性したワックス性微粉末
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5474989A (en) * 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE10199058I2 (de) * 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
JPH0696517B2 (ja) * 1993-03-17 1994-11-30 日産化学工業株式会社 変性したワックス性微粉末で被覆された薬剤及びその製造法
JP2994956B2 (ja) 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
EP2277517A1 (de) * 1996-11-15 2011-01-26 Ajinomoto Co., Inc. Nateglinide-Tablettenzubereitungen
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
JP3591801B2 (ja) * 1997-06-19 2004-11-24 田辺製薬株式会社 口腔内速崩壊性製剤の製法
JP2000178183A (ja) * 1998-12-17 2000-06-27 Lion Corp 固形製剤及びその製造方法
JP2000290171A (ja) * 1999-04-06 2000-10-17 Eisai Co Ltd 崩壊のはやい錠剤又はその製造方法
CN1437483A (zh) * 1999-12-28 2003-08-20 味之素株式会社 口服给药用糖尿病药物制剂
NZ521366A (en) * 2000-03-17 2005-07-29 Ajinomoto Kk Drugs for complications of diabetes and neuropathy, and utilisation thereof
PT1334963E (pt) * 2000-10-18 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida
BR0114728B1 (pt) * 2000-10-18 2014-01-14 Método para produzir uma acilfenilalanina
CN100352432C (zh) * 2000-10-24 2007-12-05 味之素株式会社 含有那格列奈的制剂
AU2001296001A1 (en) * 2000-10-24 2002-05-06 Ajinomoto Co., Inc. Process for producing b-form nateglinide crystal
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration

Also Published As

Publication number Publication date
ES2321911T3 (es) 2009-06-15
TWI289461B (en) 2007-11-11
PT1334721E (pt) 2009-06-01
EP1334721A4 (de) 2005-11-02
JPWO2002040010A1 (ja) 2004-06-03
MXPA03003686A (es) 2004-01-26
SI1334721T1 (sl) 2009-08-31
JP2013064018A (ja) 2013-04-11
DK1334721T3 (da) 2009-07-06
CA2426764C (en) 2010-04-20
JP2010095551A (ja) 2010-04-30
BR0114897A (pt) 2003-08-12
KR100829410B1 (ko) 2008-05-15
EP1334721B1 (de) 2009-04-22
EP1334721A1 (de) 2003-08-13
US20040029968A1 (en) 2004-02-12
CN100531730C (zh) 2009-08-26
RU2283104C2 (ru) 2006-09-10
JP5278708B2 (ja) 2013-09-04
CA2426764A1 (en) 2003-04-23
KR20030042028A (ko) 2003-05-27
AU2001296000A1 (en) 2002-05-27
WO2002040010A1 (fr) 2002-05-23
DE60138476D1 (de) 2009-06-04
JP5673972B2 (ja) 2015-02-18
CN1482904A (zh) 2004-03-17
CY1110320T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
CY1110320T1 (el) Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide)
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
ES2354244T3 (es) Proceso de preparación de formas de administración rápidamente disgregables para la liberación de principios activos en la cavidad bucal o en cavidades corporales.
AR029716A1 (es) Productos dermatologicos en forma de hoja
JP4387356B2 (ja) 超音波導入スキンケアデバイス
CA2416869A1 (en) Vaccines
ES2075249T3 (es) Dispositivo adhesivo para la administracion transdermica de un agente activo.
ATE123218T1 (de) Pharmazeutische ionenaustauscherharzzusammensetzung.
RU2000123567A (ru) Фармацевтическая композиция, содержащая в комбинации метформин и фибрат, и ее применение при приготовлении лекарственных средств, предназначенных для снижения гипергликемии
KR20040002391A (ko) 경구투여제 및 경구투여제 유지체
DE69414840D1 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
KR101489524B1 (ko) 발포성 보습 조성물
ES2193726T3 (es) Formulaciones de aerosol medicinales.
CA2320039A1 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
EP0350701A3 (de) Arzneimittel zur oralen Verabreichung mit analgetischer und antiinflammatorischer Wirkung, die einen ausgezeichneten Geschmack besitzen und frei von irritierenden Effekten auf die Schleimhäute sind
RU2003111949A (ru) Гидрофильный фармацевтический препарат, содержащий натеглинид
CA2617659A1 (en) Use of hydroxybenzoic acid esters and analogues for the manufacture of a medicament for the prevention and treatment of virus infection
DE59509928D1 (de) Antihyperglykämisch wirksame Arzneimittel
CO4700033A1 (es) Preparados de liberacion controlada a base de una sal pota- sica alcalinizante
ATE262350T1 (de) Flüssige pharmazeutische zusammensetzung zur oralen verabreichung bitterschmeckender hydrolyseempfindlicher aktivstoffe
JP2003081840A (ja) 清涼化方法、清涼化剤および外用組成物
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
WO2004037226B1 (en) Pharmaceutical compositions containing venlafaxine
ES2347257T3 (es) Enjuague bucal.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1334721

Country of ref document: EP